Suppr超能文献

递增式血液透析与血管通路并发症:医院血液透析中心 12 年经验。

Incremental hemodialysis and vascular access complications: a 12-year experience in a hospital hemodialysis unit.

机构信息

Nephrology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.

Alcalá de Henares University, Madrid, Spain.

出版信息

J Nephrol. 2024 Sep;37(7):1929-1937. doi: 10.1007/s40620-024-01932-9. Epub 2024 Jun 5.

Abstract

BACKGROUND

Incremental hemodialysis (HD) is considered a valid alternative for patients with residual kidney function. Evidence concerning its effect on vascular access is scarce. We present our 12-year experience of an incremental hemodialysis program with the aim of evaluating survival and complications of arteriovenous fistula in these patients compared to the thrice-weekly scheme.

METHODS

From January 1st, 2006 to December 31st, 2017, 220 incident patients started hemodialysis, 132 (60%) of whom began hemodialysis with two sessions per week and 88 (40%) with three sessions per week. Demographic and clinical variables were assessed at the start of treatment. Data regarding arteriovenous fistula survival and complications were collected.

RESULTS

Both groups had similar baseline sociodemographic and clinical characteristics. A total of 188 (85%) patients were dialyzed with an arteriovenous fistula during follow-up. Eighty-three patients had one or more fistula complications, with no differences between incremental and conventional groups (p = 0.55). Fistula survival rates showed no significant difference between the two groups, whether analyzed from the date of fistula creation (Log Rank p = 0.810) or from the date of initial fistula cannulation (Log Rank p = 0.695).

CONCLUSIONS

We found no differences in arteriovenous fistula survival or complication rate between patients who started HD with an incremental versus a conventional treatment scheme. Randomized controlled clinical trials may be warranted to achieve a higher degree of evidence.

摘要

背景

递增血液透析(HD)被认为是保留肾功能患者的一种有效替代方案。关于其对血管通路影响的证据很少。我们介绍了我们 12 年来递增血液透析方案的经验,旨在评估与每周三次方案相比,这些患者的动静脉瘘的存活率和并发症。

方法

从 2006 年 1 月 1 日至 2017 年 12 月 31 日,220 例新发病例开始血液透析,其中 132 例(60%)每周进行两次血液透析,88 例(40%)每周进行三次血液透析。在治疗开始时评估人口统计学和临床变量。收集动静脉瘘存活和并发症的数据。

结果

两组患者的基线社会人口统计学和临床特征相似。在随访期间,共有 188 例(85%)患者接受动静脉瘘透析。83 例患者有 1 次或多次瘘管并发症,递增组和常规组之间无差异(p=0.55)。从造瘘日期(对数秩检验 p=0.810)或从首次瘘管插管日期(对数秩检验 p=0.695)分析,两组瘘管存活率均无显著差异。

结论

我们发现,与开始常规治疗方案的患者相比,开始递增血液透析治疗的患者的动静脉瘘存活率或并发症发生率没有差异。可能需要进行随机对照临床试验以获得更高水平的证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验